Watch LUCD. Know when insiders buy.
One email the day a filing lands. Free.
LUCD
Lucid Diagnostics Inc.
0.79
+0.01 +0.77%
USD · close Sep 18
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
70
PASS · shorts 70
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $159.7MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$52.3MNET CASH $23M52W 0.78 – 1.47SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$12.8M | −$11.7M | — | -0.08 | −$11.3M | $21K | −$11.3M | Aug 12 |
| Q1 2026 · Mar 31 | — | — | — | −$12.1M | −$13.9M | — | -0.17 | −$12.1M | $215K | −$12.3M | May 13 |
| Q4 2025 · Dec 31derived | — | — | — | −$14M | −$16.3M | — | -0.10 | −$12.6M | — | — | Mar 25 |
| Q3 2025 · Sep 30 | $1.2M | +3.3% | — | −$11.8M | −$10.4M | — | -0.10 | −$10.9M | — | — | Nov 12 |
| Q2 2025 · Jun 30 | $1.2M | +19.2% | -34.4% | −$11.4M | −$4.4M | — | -0.08 | −$10.5M | $25K | −$10.6M | Aug 12 |
| Q1 2025 · Mar 31 | $828K | −17.3% | -87.3% | −$12.5M | −$26.9M | — | -0.52 | −$12.5M | $93K | −$12.6M | May 13 |
| Q4 2024 · Dec 31derived | $1.2M | +15.1% | — | −$12.4M | −$11.5M | — | -0.18 | −$9.9M | — | — | Mar 25 |
| Q3 2024 · Sep 30 | $1.2M | +49.7% | — | −$11.7M | −$12.4M | — | -0.25 | −$10.2M | — | — | Nov 12 |
| Q2 2024 · Jun 30 | $976K | — | — | −$11.2M | −$11M | — | -0.23 | −$11.5M | — | — | Aug 12 |
| Q1 2024 · Mar 31 | $1M | — | — | −$10.8M | −$10.6M | — | -0.40 | −$12.6M | — | — | May 13 |
| Q4 2023 · Dec 31derived | $1M | — | — | −$11.5M | −$10.8M | — | -0.25 | −$10M | — | — | Mar 24 |
| Q3 2023 · Sep 30 | $783K | — | — | −$11.1M | −$14.2M | — | -0.34 | −$8.8M | — | — | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$49.6M | −$58M | — | -0.69 | −$46.5M | $197K | −$46.7M | — | — |
| FY2024 · to Dec 31 | $4.3M | -63.3% | −$46.1M | −$45.5M | -1047.6% | -1.05 | −$44.1M | $296K | −$44.4M | — | — |
| FY2023 · to Dec 31 | $2.4M | — | −$48.5M | −$52.7M | -2169.1% | -1.26 | −$32.8M | — | — | — | — |
| FY2022 · to Dec 31 | $377K | 100.0% | −$56.3M | −$56.2M | -14899.5% | -1.55 | −$29.7M | $3.2M | −$32.9M | — | — |
| FY2021 · to Dec 31 | $500K | 100.0% | −$27.4M | −$28.1M | -5615.6% | -1.51 | −$17.7M | $862K | −$18.5M | — | — |
| FY2020 · to Dec 31 | — | — | −$8.3M | −$8.3M | — | -0.59 | −$5.6M | — | — | — | — |
Every number comes from Lucid Diagnostics Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.